MedTrace Logo

Inflammation and Brain Function - Pilot Study

NCT03551080 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-06-11

No results posted yet for this study

Summary

In this randomized double blind cross-over study 8 healthy persons were injected with 0.8 ng/kg body weight lipopolysaccharide (LPS) /endotoxin and placebo at two different occasions. The aim was to investigate how pain sensitivity and health perception change in response to an acute immune activation.

Conditions

  • Sickness Behavior

Interventions

BIOLOGICAL

Lipopolysaccharide

Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)

BIOLOGICAL

Placebo

Saline administered intravenously

Sponsors & Collaborators

  • University of California, San Francisco

    collaborator OTHER

  • The Swedish Society of Medicine

    collaborator OTHER

  • Swedish Heart Lung Foundation

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Swedish Council for Working Life and Social Research

    collaborator OTHER

  • Stockholm University

    collaborator OTHER

  • Karolinska Institutet

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03551080 on ClinicalTrials.gov